

Molecular Typing of IberoAmerican *Cryptococcus neoformans* Isolates

Wieland Meyer,* Alexandra Castañeda,† Stuart Jackson,*‡ Matthew Huynh,* Elizabeth Castañeda,† and the IberoAmerican Cryptococcal Study Group¹

A network was established to acquire basic knowledge of *Cryptococcus neoformans* in IberoAmerican countries. To this effect, 340 clinical, veterinary, and environmental isolates from Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela, Guatemala, and Spain were typed by using M13 polymerase chain reaction-fingerprinting and orotidine monophosphate pyrophosphorylase (*URA5*) gene restriction fragment length polymorphism analysis with *HhaI* and *Sau96I* in a double digest. Both techniques grouped all isolates into eight previously established molecular types. The majority of the isolates, 68.2% (n=232), were VNI (var. *grubii*, serotype A), which accords with the fact that this variety causes most human cryptococcal infections worldwide. A smaller proportion, 5.6% (n=19), were VNII (var. *grubii*, serotype A); 4.1% (n=14), VNIII (AD hybrid), with 9 isolates having a polymorphism in the *URA5* gene; 1.8% (n=6), VNIV (var. *neoformans*, serotype D); 3.5% (n=12), VGI; 6.2% (n=21), VGII; 9.1% (n=31), VGIII, and 1.5% (n=5) VGIV, with all four VG types containing var. *gattii* serotypes B and C isolates.

Cryptococcosis is among the most prevalent life-threatening mycoses and has a worldwide distribution. The etiologic agent is the basidiomycetous yeast *Cryptococcus neoformans* (1,2); three varieties are recognized: *C. neoformans* var. *grubii*, serotype A (3), *C. neoformans* var. *neoformans*, serotype D, *C. neoformans* var. *gattii*, serotypes B and C, and the hybrid serotype AD (4).

Humans are infected by inhaling infectious propagules from the environment, which primarily colonize the lung and subsequently invade the central nervous system (4). *C. neoformans* var. *grubii/neoformans* has been isolated worldwide from soil enriched with avian excreta (4,5). More recently, decaying wood from certain species of trees has been proposed as environmental habitat for this variety (6). In contrast, the distribution in nature for *C. neoformans* var. *gattii* is geographically restricted to mainly tropical and subtropical regions (7,8). To date, specific host trees are represented by *Eucalyptus* species, *Moquilea tomentosa*, *Cassia grandis*, *Ficus microcapra*, and *Terminalia catappa* (7–11).

Worldwide, in immunocompromised hosts, most infections are caused by *C. neoformans* var. *grubii* (4,5). In contrast, *C. neoformans* var. *gattii* virtually always affects immunocompetent hosts (8).

In the last decade, a number of DNA typing techniques have been used to study the epidemiology of *C. neoformans*. These techniques include karyotyping, random amplification of polymorphic DNA, restriction fragment length polymorphism (RFLP), DNA hybridization studies, amplified fragment length polymorphism (AFLP), and polymerase chain reaction (PCR) fingerprinting (12–17).

PCR fingerprinting has been used as the major typing technique in the ongoing global molecular epidemiologic survey of *C. neoformans* (14,18), dividing >400 clinical and environmental isolates into eight major molecular types: VNI (var. *grubii*, serotype A), VNII (var. *grubii*, serotype A), VNIII (serotype AD), VNIV (var. *neoformans*, serotype D), VGI, VGII, VGIII, and VGIV (var. *gattii*, serotypes B and C). No correlation between serotype and molecular type has been found for *C. neoformans* var. *gattii*. The molecular types were recently confirmed by RFLP analysis of the orotidine monophosphate pyrophosphorylase (*URA5*) gene and the phospholipase (*PLBI*) gene (19).

Globally, most of the isolates recovered from AIDS patients belong to the genotypes VNI and VNIV, whereas the genotypes VNI and VGI are predominant throughout the world for *C. neoformans* var. *grubii* and *C. neoformans* var. *gattii*, respectively. The larger number of genotype VNI isolates agrees with the fact that *C. neoformans* var. *grubii* causes most human cryptococcal infections worldwide (18,19).

The aims of this study were the following: 1) to extend the molecular epidemiologic survey to other parts of the world, 2) to establish a regional network of participating reference laboratories, and 3) to apply PCR fingerprinting and *URA5* RFLP typing to investigate the genetic structure and possible epidemiologic relationships between clinical and environmental isolates obtained in Latin America and Spain. The results of this study permitted us to determine the major molecular types and their distribution within each participating country.

¹Members of the IberoAmerican Cryptococcal Study Group: *Argentina*: Alicia Arechavala, Hospital de Infecciosas Francisco J. Muñiz, Buenos Aires; Graciela Davel, Laura Rodero, Diego Perrotta, Departamento Micología, Instituto Nacional de Enfermedades Infecciosas "Dr. Carlos Gregorio Malbrán," Buenos Aires; *Brazil*: Marcia Lazera, Ricardo Pereira-Igreja, Bodo Wanke, Laboratorio de Micología Médica, Hospital Evandro Chagas, FundaVao Oswaldo Cruz, Rio de Janeiro; Maria Jose Mendes-Giannini, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista (UNESP), Araraquara; Marcia S.C. Melhem, Adolfo Lutz Institute SeVao de Micologia, São Paulo; Marlene Henning-Vainstein, Centro de Biotecnología (UFRGS), Porto Alegre; *Chile*: Maria Cristina Diaz, Programa de Microbiología y Micología, Universidad de Chile, Santiago; *Colombia*: Angela Restrepo, Corporación para Investigaciones Biológicas, Medellín; Sandra Huertano, Instituto Nacional de Salud, Bogotá; *Guatemala*: Blanca Samayoa, Hospital San Juan de Dios, Guatemala City; Heidi Logeman, Universidad de San Carlos, Guatemala City; *Mexico*: Rubén López Martínez, Laura Rocio Castañón Olivares, Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, México City; Cudberto Contreras-Peres, José Francisco Valenzuela Tovar, Instituto Nacional de Diagnóstico y Referencia Epidemiológicos, México City; *Peru*: Beatriz Bustamante, Instituto de Medicina Tropical Alexander Humboldt, Lima; *Spain*: Joseph Torres-Rodriguez, Yolanda Morera, Grup de recerca en Micologia Experimental i Clínica, Institut Municipal d'Investigació Mèdica, Universitat Autònoma de Barcelona, Barcelona; *Venezuela*: Belinda Calvo, Universidad del Zulia, Maracaibo.

*University of Sydney, Sydney, Australia; †Instituto Nacional de Salud, Bogotá, Colombia; and ‡University of Western Sydney, Campbelltown, Australia

Materials and Methods

Study Design

During the 12th International Society for Human and Animal Mycoses meeting in Buenos Aires, Argentina, in March 2000, it was decided to establish an IberoAmerican Cryptococcal Study Group under the coordination of E. Castañeda and W. Meyer. Each of the participating laboratories was asked to submit 10–30 isolates. For the clinical isolates, the following data were requested: isolation date, demographic data (age and gender of patient), collection location, risk factors, source and variety, and serotype. For the environmental and veterinary isolates, the data collected included isolation date, source, collection location, variety, and serotype.

Fungal Isolates

An online appendix of cryptococcal isolates studied in this study is available at: URL: http://www.cdc.gov/ncidod/EID/vol9no2/02-0246_app.htm. The isolates were obtained by the participating laboratories of the IberoAmerican Cryptococcal Study Group and maintained on Sabouraud dextrose agar slants at 4°C and as water cultures at room temperature. Isolates were identified as *C. neoformans* by using standard methods (20). The variety was determined by the color reaction test on L-canavanine-glycine-bromothymol blue medium (21), and the serotype was determined, in selected isolates, by the use of the Crypto Check Kit (Iatron Laboratories Inc., Tokyo, Japan).

The isolates were sent for molecular typing to the Molecular Mycology Laboratory at the University of Sydney at Westmead Hospital, Sydney, Australia, either as water cultures or on Sabouraud dextrose agar slants. For long-term storage, the isolates were maintained as glycerol stocks at –70°C.

Reference Strains

A set of laboratory standard *C. neoformans* reference strains representing each molecular type were used in PCR fingerprinting and *URA5* RFLP as follows: WM 148 (serotype A, VNI), WM 626 (serotype A, VNII), WM 628 (serotype AD, VNIII), WM 629 (serotype D, VNIV), WM 179 (serotype B, VGI), WM 178 (serotype B, VGII), WM 161 (serotype B, VGIII), and WM 779 (serotype C, VGIV) (14).

DNA Extraction

High-molecular-weight DNA was isolated as described previously (14). Briefly, *C. neoformans* isolates were grown on Sabouraud's dextrose agar at 37°C for 48 h, a loopful of cells from the culture was mixed with sterile deionized water and centrifuged. The supernatant was discarded, and the tube containing the yeast cell pellet was frozen in liquid nitrogen. The pellet was ground with a miniature pestle. The cell lysis solution (100 mg triisopropyl naphthalene sulfonic acid, 600 mg para-aminosalicylic acid, 10 mL sterile deionized water, 2.5 mL extraction buffer (1 M Tris-HCl, 1.25 M NaCl, 0.25 M EDTA, pH 8.0) and 7.5 mL phenol saturated with Tris-EDTA was preheated to 55°C, and 700 µL of this mixture was added

to the frozen, ground cells. The tubes were incubated for 2 min at 55°C, shaken occasionally, and then 500 µL chloroform was added, and the mixture was incubated for a 2 min at 55°C and shaken occasionally. The tubes were centrifuged for 10 min at 14,000 rpm, and the aqueous phase was transferred to a new tube. Then, 500 µL of phenol-chloroform-isoamyl alcohol (25:24:1) was added, shaken for 2 min at room temperature, and centrifuged as above. The aqueous phase was transferred to a new tube, 500 µL of chloroform was added, shaken, and centrifuged as above. To precipitate the genomic DNA, the aqueous phase was again transferred to a new tube, and 0.03 volumes 3.0 M sodium acetate (pH 5.2) and 2.5 volumes cold 96% ethanol were added, and the mixture was gently shaken and incubated at –20°C for at least 1 h or overnight. The solution was centrifuged for 30 min at 14,000 rpm to pellet the DNA. The DNA pellet was washed with 70% ethanol and centrifuged for 10 min at 14,000 rpm and air-dried. The DNA was resuspended in 200 µL sterile deionized water at 4°C overnight and stored at –20°C.

PCR Fingerprinting

The minisatellite-specific core sequence of the wild-type phage M13 (5' GAGGGTGGCGGTTCT 3') (22) was used as single primer in the PCR. The amplification reactions were performed in a volume of 50 µL containing 25 ng high-molecular-weight genomic DNA, 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 0.2 mM each of the dATP, dCTP, dGTP and dTTP (Roche Diagnostics GmbH, Mannheim, Mannheim, Germany), 3 mM magnesium acetate, 30 ng primer, and 2.5 U AmpliTaq DNA polymerase (Applied Biosystems, Foster City, CA). PCR was performed for 35 cycles in a Perkin-Elmer thermal cycler (model 480) with 20 s of denaturation at 94°C, 1 min annealing at 50°C, and 20 s extension at 72°C, followed by a final extension cycle for 6 min at 72°C. Amplification products were removed, concentrated to approximately 20 µL and separated by electrophoresis on 1.4% agarose gels (stained with ethidium bromide, 10 mg/mL stock) in 1X Tris-borate-EDTA (TBE) buffer at 60 V for 14 cm, and visualized under UV light (14). Molecular types (VNI–VNIV and VGI–VGIV) were assigned, according to the major bands in the patterns. All visible bands were included in the analysis, independent of their intensity (14,18).

URA5 Gene RFLP

PCR of the *URA5* gene was conducted in a final volume of 50 µL. Each reaction contained 50 ng of DNA, 1X PCR buffer (10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂; Applied Biosystems, Foster City, CA), 0.2 mM each of dATP, dCTP, dGTP, and dTTP (Roche Diagnostics GmbH), 3 mM magnesium acetate, 1.5 U AmpliTaq DNA polymerase (Applied Biosystems), and 50 ng of each primer *URA5* (5' ATGTCCTC-CCAAGCCCTCGACTCCG 3') and SJ01 (5' TTAAGAC-CTCTGAACACCGTACTC 3'). PCR was performed for 35 cycles in a Perkin-Elmer thermal cycler (model 480) at 94°C for 2-min initial denaturation, 45 s of denaturation at 94°C, 1 min

annealing at 61°C, and 2-min extension at 72°C, followed by a final extension cycle for 10 min at 72°C. Amplification products were mixed with one fifth volume of loading buffer (15% Ficoll 400, 0.25% orange G, MilliQ water), 15 µL of PCR products were double digested with *Sau96I* (10 U/µL) and *HhaI* (20 U/µL) for 3 h or overnight and separated by 3% agarose gel electrophoresis at 100 V for 5 h. RFLP patterns were assigned visually by comparing them with the patterns obtained from the standard strains (VNI-VNIV and VGI-VGIV) (Jackson et al. unpub. data).

Statistical Analysis

Initially, individual PCR fingerprints were visually compared to those of the standard strains, amplified in parallel, to determine the major molecular type for each isolate. The computer program *GelComparII*, version 1.01 (Applied Maths, Kortrijk, Belgium) was used to determine the genetic relationship of the strains. DNA bands of each fingerprint pattern were defined manually with a band-position tolerance of 0.9%, being the optimal settings needed to define the molecular size marker bands as 100% identical. Similarity coefficients were calculated by using the Dice algorithm, and cluster analyses were performed by the neighbor-joining algorithms by using the “Fuzzy Logic” and “Area Sensitive” option of the *GelcomparII* program.

Results

During the course of this investigation, a network was established with 15 laboratories from nine countries participating in this study. The participant countries were: Argentina, Brazil, Chile, Colombia, Guatemala, Mexico, Peru, Spain, and Venezuela.

A total of 340 *C. neoformans* isolates, comprising 266 clinical, 7 veterinary, and 67 environmental isolates were submitted for molecular typing. Of these, 57 were from Argentina (53 clinical and 4 environmental), 66 from Brazil (56 clinical, 9 environmental, and 1 veterinary), 19 from Chile (15 clinical and 4 environmental), 62 from Colombia (39 clinical and 23 environmental), 15 from Guatemala (all clinical), 69 from Mexico (46 clinical and 23 environmental), 13 from Peru (all clinical), 19 from Spain (9 clinical, 6 veterinary, and 4 environmental), and 20 from Venezuela (all clinical). From the total isolates investigated, 271 (79.6%) were *C. neoformans* var. *grubii/neoformans*; 251 (92.6%) of them were *C. neoformans* var. *grubii*, 6 (1.8%) were *C. neoformans* var. *neoformans*, and 13 (4.8%) were AD hybrid isolates. The remaining 69 (20.4%) isolates were *C. neoformans* var. *gattii*.

All 340 isolates were typed by PCR fingerprinting by using the minisatellite-specific oligonucleotide M13 as a single primer and RFLP analysis of the *URA5* gene with the restriction enzymes *Sau96I* and *HhaI* in a double digest. The molecular types were determined for each isolate by comparing the obtained PCR fingerprint profiles and *URA5* RFLP patterns with the respective standard patterns for each molecular type.

The serotyping results (Iatron) correlated with the molecular subtyping results in all serotype B (n=31) and C (n=13) iso-

lates. Regarding serotype A, 99 from a total of 102 (97%) isolates correlated; the remaining 3 were serotype A by the Iatron and serotype AD by the molecular typing method. Regarding serotype D, one of four reported was confirmed by molecular typing; the other three were serotype AD. For serotype AD, two isolates were found when typed with the Iatron kit and eight when typed with molecular typing techniques. All the changes were found in the isolates from Spain. This finding is not surprising, taking into account that problems with the serotyping concerning potential serotype AD hybrids are known (4). A list of the characteristics of the studied isolates by participating country, laboratory, laboratory code, clinical, veterinary or environmental origin, isolate characteristics (isolation year, isolation location, source, gender, age and risk factor), variety, serotype and the molecular type identified during this study is available in an online appendix (http://www.cdc.gov/ncidod/EID/vol9no2/02-0246_app.htm).

Both molecular typing techniques grouped the isolates in the eight previously established major genotypes (Figures 1 and 2). From the isolates investigated, 232 (68.2%) were molecular type VNI (serotype A, var. *grubii*), 19 (5.6%) were molecular type VNII (serotype A, var. *grubii*), 14 (4.1%) were molecular type VNIII (serotype A/D, hybrid between the serotypes A and D), with 5 having a RFLP pattern of the *URA5* gene with seven bands, indicated by VNIII in the online Appendix and Figure 3B and 4B, corresponding to a hybrid between VNI, VNII, and VNIV and 9 isolates having an RFLP pattern of the *URA5* gene with six bands, indicated by VNIII* in the online Appendix and Figure 4B and 5B, corresponding to a hybrid between VNII and VNIV, 6 (1.8%) were molecular type VNIV (serotype D, var. *neoformans*), 12 (3.5%) were molecular type VGI (serotypes B and C, var. *gattii*), 21 (6.2%) were molecular type VGII (serotypes B and C, var. *gattii*), 31 (9.1%) were molecular type VGIII (serotypes B and C, var. *gattii*), and 5 (1.5%) were molecular type VGIV (serotypes B and C, var. *gattii*).

Figures 3A and 4A show examples of PCR fingerprints obtained from Mexican and Spanish isolates; Figures 3B and 4B show the corresponding *URA5* RFLP patterns for the same isolates. The Mexican isolates were selected because they were representative of the patterns observed from all the isolates submitted by the Latin American participating laboratories. The Spanish isolates were selected because they represented a distribution of molecular types corresponding to those observed in previous studies on European isolates (14).

From the 340 isolates studied 277, marked with “#” in the online Appendix, have been included in the *GelComparII* analysis. Sixty-three isolates were excluded from the analysis since their PCR fingerprinting patterns were not sharp or had been run under slightly different electrophoresis conditions, making the band positions impossible to compare. Cluster analysis of the PCR-fingerprinting profiles by using the *GelComparII* program grouped all isolates into three major clusters according to variety and into eight major groups according to the molecular type. The overall homology observed was 50.4% among isolates of *C. neoformans* var.




Figure 1. Geographic distribution of the molecular types obtained from IberoAmerican *Cryptococcus neoformans* isolates by polymerase chain reaction fingerprinting and *URA5* gene restriction fragment length polymorphism analysis (total numbers studied per country given in parentheses).

grubii, 50.9% for *C. neoformans* var. *neoformans*, and 51.2% for *C. neoformans* var. *gattii* (Figure 2). The homology within a given molecular type was as follows: 54.8% VNI, 57.3% VNII, 51.9% VNIII, 50.9% VNIV, 56.4% VGI, 56.4% VGII, 54.4% VGIII, and 68.3% VGIV.

Besides grouping all isolates into the eight major molecular patterns, the molecular type VNI could be subdivided into eight main subclusters, with most of these subclusters' grouping isolates obtained from specific countries. The similarity between isolates obtained from any individual country varied from 65% to 82%. Most of the main subclusters within molecular type VNI also contained isolates from different countries, indicating gene flow and strain dispersal between South American countries, Spain, or both. However, all isolates could be separated by their unique PCR-fingerprinting pattern, with the highest homology being 84% between two unrelated environmental isolates from Mexico City (LA 22, budgerigar [parakeet] droppings, and LA 25, pigeon droppings).

Of the 266 clinical isolates, 177 (66.5%) were obtained from HIV-positive patients, with 139 (78.5%) being VNI, 14 (7.9%) VNII, 13 (7.4%) VNIII, 6 (3.4%) VNIV, 3 (1.7%) VGII, and 2 (1.1%) VGIII. Most (86.4%) isolates from HIV-positive patients belonged to the molecular types VNI and VNII, representing serotype A, *C. neoformans* var. *grubii*. Of these, 266 clinical isolates, 51 (19.2%) were recovered from patients with no reported risk factors. From those, 23 (45.1%) were var. *grubii* with the molecular type VNI (n=21) or VNII (n=2), and 28 (54.9%) were var. *gattii* with the molecular types VGI (n=3), VGII (n=10), VGIII (n=14), and VGIV (n=1). For 26 of the clinical isolates, no data concerning risk factors were available. Six veterinary isolates were molecular type VGI, and one was VGII. Most of the environmental isolates belonged to *C. neoformans* var. *grubii* with 73.1% being VNI (n=49) and 1.5%

VNIII (n=1) AD hybrids. The remaining 17 (25.3%) isolates were *C. neoformans* var. *gattii* with the molecular type VGI (n=1), VGII (n=3), VGIII (n=12), and VGIV (n=1).

Cryptococcal isolates included in the IberoAmerican study were more frequently obtained from men than from women. The male-to-female ratio was 211 to 41, i.e., cryptococcosis was 5.1 times more common in men than in women. In the HIV-positive population alone, the incidence of cryptococcosis was 5.5 times more frequent in men than in women, based on the data obtained from the isolates investigated in this study. The age of the patients with clinically manifested cryptococcosis ranged from 4 to 73; 175 (65.9%) were between 21 and 40 years old.

The clinical isolates submitted to this study were collected over a period of 41 years, 1961–2001; most (92.5%) of the isolates were collected in the mid-1990s. The veterinary isolates were recovered from goats in Spain in 1995 and from a parrot in Brazil in 2000. The environmental isolates submitted were collected over a period of 7 years, 1993–2000.

Discussion

This retrospective study of cryptococcosis in IberoAmerica was set up in an effort to establish a network of medical




Figure 2. Dendrogram of the polymerase chain reaction-fingerprinting patterns obtained with the primer M13 from a selection of the IberoAmerican isolates studied. All the isolates fall into eight major molecular types, which fall into three major groups corresponding to *Cryptococcus neoformans* var. *grubii*, serotype A, with two molecular types VNI and VNII; *C. neoformans* var. *neoformans*, serotype D, with the molecular type VNIV; and *C. neoformans* var. *gattii* serotypes B and C, with the molecular types VGI, VGII, VGIII and VGIV. In addition to the three major clusters we can see the intermediate molecular type VNIII, representing the AD hybrids.




Figure 3. Polymerase chain reaction (PCR) fingerprints generated with the primer M13 (3A), and *URA5* gene restriction fragment length polymorphism (RFLP) profiles identified by double digest of the gene with *Sau961* and *HhaI* (3B) obtained from a selection of Mexican *Cryptococcus neoformans* isolates, given as a representative example for the patterns obtained from clinical and environmental isolates from Latin America. Standard patterns obtained from the reference strains of the major molecular types by PCR-fingerprinting patterns with the microsatellite specific primer M13 as a single primer in the PCR (right-hand side of 3A) and *URA5* gene RFLP profiles generated after double digest with *Sau961* and *HhaI* (right-hand side of 3B) (VNIII correspond to the seven-band *URA5* RFLP pattern and VNIII* correspond to the six-band *URA5* RFLP pattern).

mycology laboratories to study the distribution of cryptococcal isolates, including the varieties and molecular types within the participating countries. The network was aimed at generating PCR-fingerprint and *URA5* RFLP patterns under standardized conditions in the Molecular Mycology Laboratory of the University of Sydney at Westmead Hospital, for a subset of clinical and environmental *C. neoformans* isolates from each participating country. These reference profiles are now available to each participating laboratory so they can set up the molecular typing techniques in their own laboratories, and to serve as internal controls in future extended studies of cryptococcal isolates in each country.

The data were obtained from a random selection of cryptococcal isolates from each participating country and laboratory, which do not necessarily reflect the true situation in IberoAmerica. Nonetheless, the data offer a general overview of molecular types and variety distribution of *C. neoformans* in IberoAmerica. For the first time, two different molecular typing techniques, PCR-fingerprinting with the minisatellite specific primer M13 and *URA5* gene RFLP analysis, were applied simultaneously to the same set of cryptococcal iso-

lates, demonstrating identical groupings to the eight major molecular types previously described (14,18).

Previous pilot studies that used PCR-fingerprinting at the University of Sydney at Westmead Hospital distributed more than 400 clinical and environmental isolates obtained from Argentina, Australia, Belgium, Brazil, Germany, Italy, New Zealand, Papua New Guinea, South Africa, Thailand, Uganda, and the United States in eight major molecular types, VNI and VNII (serotype A), VNIII (serotype AD), VNIV (serotype D), VGI, VGII, VGIII and VGIV (serotypes B and C) (14,18). At the time of this original work, the molecular types VNI and VGI were found to be the most common genotypes worldwide. The present study, which includes more isolates from Latin America, showed the same results as regards variety *grubii*, with VNI being the predominant molecular type, accounting for 68.2% of all isolates. However, the situation changed drastically for variety *gattii*, as in this study, the predominant molecular type was VGIII, accounting for 9.1% of all isolates, in contrast to previous studies which showed that the molecular type VGIII was geographically restricted to India and the United States (18,19). In the present study, VGIII was also found in Argentina, Colombia, Guatemala, Mexico




Figure 4. Polymerase chain reaction fingerprints generated with the primer M13 (4A) and *URA5* gene restriction fragment length polymorphism (RFLP) profiles identified via double digest of the gene with *Sau961* and *HhaI* (4B) obtained from the Spanish clinical, veterinary, and environmental *Cryptococcus neoformans* isolates (VNIII correspond to the seven-band *URA5* RFLP pattern and VNIII* correspond to the six-band *URA5* RFLP pattern). 100bp MassRuler used as molecular marker in 4B.

and Venezuela, suggesting that it is not as limited as previously suggested. The same was true for the molecular type VGIV, previously assigned only to India and South Africa (18,19); its presence in Colombia and Mexico, although in very low numbers, indicates a wider geographic distribution.

In general, the most common variety was *C. neoformans* var. *grubii*, 73.8% (n=251), followed by variety *gattii*, 20.3% (n=69). Much less common were the AD hybrids, 4.1% (n=14) and variety *neoformans*, 1.8% (n=6), which reflects the global distribution previously established (14,18,23).

The overall grouping of the isolates into eight major molecular types by PCR-fingerprinting with the minisatellite specific primer M13, obtained in this study and the previous pilot study by Meyer et al. 1999 (14) and Ellis et al. 2000 (18), agrees with the findings by Boekhout et al. 2001 (23) and by Cogliati et al. in 2000 (24). Boekhout et al. (23) used AFLP analysis to study 206 global isolates of *C. neoformans*, and grouped them into six major AFLP groups, whereas Cogliati et al. (24), using a slightly modified PCR-fingerprinting technique with the microsatellite specific primer (GACA)₄, grouped Italian isolates of *C. neoformans* var. *grubii* and var. *neoformans* into four major molecular types. Comparable molecular/genotypes, which were identified in the four cited independent studies, are VNI = AFLP1 = Cogliati VN6 (serotype A, var. *grubii*); VNII = AFLP1A (serotype A, var. *grubii*); VNIII = AFLP3 = Cogliati VN3 and VN4 (serotype AD, hybrid between var. *grubii* and var. *neoformans*); VNIV = AFLP2 = Cogliati VN1 (serotype D, var. *neoformans*); VGI = AFLP4, VGII = AFLP6, VGIII = AFLP5 and VGIV (all corresponding to serotypes B and C, var. *gattii*) (14,18,23,24).

The overall results show some clonality between isolates obtained from a certain country or even between different countries, suggesting partial clonal spread of the pathogenic yeast within South America. However, the approximately 50%, overall similarity between *C. grubii* isolates, with the highest being 82%, suggests that these South American isolates are more varied than those obtained in a previous study by Franzot et al. (25), in which they examined a limited number of isolates from Brazil by using less discriminatory molecular techniques (CNRE-1 RFLP analysis and *URA5* sequencing). In Franzot's study, the highest similarity was >94% between the Brazilian isolates, suggesting a higher clonality than observed in the isolates obtained from New York City studied in the same paper (25).

Interestingly, Chile and Spain share similar molecular types. Both countries have a large number of molecular type VNIII isolates (AD hybrids), 15.8% and 42.1%, respectively, although VNIV serotype D isolates were present only in Chile (26.3%). These groups are usually common in a number of European countries, such as France and Italy (26–28). However, only these two countries show two different *URA5* RFLP patterns, one consisting of seven bands, indicating a hybrid between VNI, VNII, and VNIV, and a second new hybrid *URA5* RFLP pattern, consisting of six bands, indicating a hybrid between VNII and VNIV. As a result of the IberoAmeri-

can study, these hybrid patterns had recently been reported as part of Jackson's honor's thesis work (Jackson and Meyer unpub. data, 2000). The seven-band *URA5* RFLP pattern was exclusively found in Spain (n=3) and Chile (n=2). These strains seem to be triploid, and cloning with subsequent sequencing of the PCR product showed that they contain three different copies of the *URA5* gene. The six-band *URA5* RFLP pattern found in Spain (n=5) and Chile (n=1), was also found in Mexico (n=1) and Argentina (n=2), possibly due to the presence of the molecular types VNII and VNIV in these countries (14). These hybrid isolates are diploid at the *URA5* locus and contain two different copies of the gene (Jackson and Meyer, unpub. data).

Further studies are needed to investigate the special relationship between isolates obtained from these two countries. The similarity in the molecular types obtained from Spanish and Chilean isolates provides further evidence, that the cryptococcal strains present today in South America could be introduced during the European colonization. This idea had been suggested by Franzot et al. (25) when investigating isolates obtained from Brazil. The authors argue that the pigeon (*Columba livia*), thought to provide a major reservoir of *C. neoformans* in pigeon excreta, is believed to have originated in southern Europe and northern Africa and has been dispersed worldwide by human travel (29).

Most of the cryptococcal isolates in this study were recovered from patients whose main risk factor was HIV infection. Overwhelming numbers of these isolates corresponded to the molecular type VNI, in accordance with previous findings, showing that isolates of this molecular type are the major source of infection in HIV-positive patients worldwide (18,19). This finding highlights the fact that most human cryptococcal infections are caused by *C. neoformans* var. *grubii*, serotype A (4,5). A distinct picture emerged in the group of isolates obtained from patients with no known risk factors, as most were *C. neoformans* var. *gattii* isolates (n=28), with the molecular types VGI (n=3), VGII (n=10), VGIII (n=14), and VGIV (n=1), compared to 23 isolates belonging to the overall most common molecular type, VNI (41.2%) of *C. neoformans* var. *grubii*. This finding supports the conclusion that variety *gattii* primarily infects immunocompetent patients as Chen et al. had found when investigating Australian isolates (30). These authors have proposed that aboriginal people living in rural areas of Australia's Northern Territory have a higher risk of cryptococcosis because they live in close proximity to the potential natural host of *C. neoformans* var. *gattii*, the eucalyptus trees (30).

Despite the fact that isolates included in this study constituted a random sampling, the results show again that HIV infection is the most important risk factor for cryptococcosis (31). This conclusion is supported by the number of isolates recovered from HIV-positive patients (n=177), the age distribution, which peaks between 20 and 40 years of age, and the date of isolation with a peak corresponding to the 1990s.

Overall, the network of mycology laboratories established in IberoAmerica provided, for the first time, a baseline knowl-

edge of *C. neoformans* variety and molecular type distribution in the participating countries, placing the IberoAmerican isolates in the global picture of cryptococcosis.

Acknowledgments

We thank Krystyna Maszewska and Heide-Marie Daniel for their support in maintaining the cultures and Sarah Kidd for her help with the GelComparII program.

The work was supported by an NH&MRC grant # 990738, Canberra, Australia, to W.M., an International Society of Human and Animal Mycology training fellowship to A.C., and a travel award from Colciencias, Bogotá, Colombia, to E.C.

Dr. Meyer is the chief scientist of the Molecular Mycology Laboratory at the University of Sydney at Westmead Hospital, Sydney, Australia. His research is directed toward the phylogenetic analysis and development of molecular typing methods for epidemiologic studies of fungi; the early identification of pathogenic yeasts in pure culture and directly from clinical specimens; and molecular studies into virulence mechanisms and the pathogenicity of *Cryptococcus neoformans*.

References

- Kwon-Chung KJ. A new genus, *Filobasidiella*, the perfect state of *Cryptococcus neoformans*. *Mycologia* 1975;67:1197–200.
- Kwon-Chung KJ. A new genus, *Filobasidiella*, the sexual state of *Cryptococcus neoformans* B and C serotypes. *Mycologia* 1976;68:942–6.
- Franzot SP, Salkin IF, Casadevall A. *Cryptococcus neoformans* var. *grubii*: separate varietal status for *Cryptococcus neoformans* serotype A isolates. *J Clin Microbiol* 1999;37:838–40.
- Casadevall A, Perfect JR. *Cryptococcus neoformans*. Washington: ASM Press; 1998.
- Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS—100 years after the discovery of *Cryptococcus neoformans*. *Clin Microbiol Rev* 1995;8:515–48.
- Lazera MS, Pires FDA, Camillo-Coura L, Nishikawa MM, Bezerra CCF, Trilles L, et al. Natural habitat of *Cryptococcus neoformans* var. *neoformans* in decaying wood forming hollows in living trees. *J Med Vet Mycol* 1996;34:127–31.
- Ellis DH, Pfeiffer TC. Natural habitat of *Cryptococcus neoformans* var. *gattii*. *J Clin Microbiol* 1990;28:1642–4.
- Sorrell TC. *Cryptococcus neoformans* variety *gattii*. *Med Mycol* 2001;39:155–68.
- Lazera M, Cavalcanti M, Trilles L, Nishikawa M, Wanke B. *Cryptococcus neoformans* var. *gattii*—evidence for a natural habitat related to decaying wood in a pottery tree hollow. *Med Mycol* 1998;36:112–9.
- Lazera MS, Salmito MA, Londero AT, Trilles L, Nishikawa M, Wanke B. Possible primary ecological niche of *Cryptococcus neoformans*. *Med Mycol* 2000;38:379–83.
- Callejas A, Ordóñez N, Rodríguez MC, Castañeda E. First isolation of *Cryptococcus neoformans* var. *gattii*, serotype C, from the environment in Colombia. *Med Mycol* 1998;36:341–4.
- Brandt ME, Hutwagner LC, Kuykendall RJ, Pinner WS. Comparison of multilocus enzyme electrophoresis and random amplified polymorphic DNA analysis for molecular subtyping of *Cryptococcus neoformans*. *J Clin Microbiol* 1995;33:1890–5.
- Crampin AC, Mathews RC, Hall D, Evans EG. PCR fingerprinting *Cryptococcus neoformans* by random amplification of polymorphic DNA. *Journal of Medical and Veterinary Mycology* 1993;31:463–5.
- Meyer W, Maszewska K, Amirmostofina M, Igreja RP, Hardtke C, Methling K, et al. Molecular typing of global isolates of *Cryptococcus neoformans* var. *neoformans* by PCR-fingerprinting and RAPD. A pilot study to standardize techniques on which to base a detailed epidemiological survey. *Electrophoresis* 1999;20:1790–9.
- Currie BP, Freundlich IF, Casadevall A. Restriction fragments length polymorphism analysis of *Cryptococcus neoformans* isolates from environmental (pigeons excreta) and clinical sources in New York City. *J Clin Microbiol* 1994;32:1188–92.
- Spitzer SG, Spitzer ED. Characterization of the CNRE-1 family of repetitive DNA elements in *Cryptococcus neoformans*. *Gene* 1994;144:103–6.
- Varma A, Kwon-Chung KJ. DNA probes for strain typing of *Cryptococcus neoformans*. *J Clin Microbiol* 1992;30:2960–7.
- Ellis D, Marriott D, Hajjeh RA, Warnock D, Meyer W, Barton R. Epidemiology: surveillance of fungal infections. *Med Mycol* 2000;38:173–82.
- Meyer W, Kidd S, Castañeda A, Jackson S, Huynh M, Latouche GN, et al. Global molecular epidemiology offers hints towards ongoing speciation within *Cryptococcus neoformans*. In: Abstracts of the 5th International Conference on *Cryptococcus* and Cryptococcosis, Adelaide, Australia, March 3–7, 2002. Adelaide: South Australian Postgraduate Medical Education Association; 2002.
- Kwon-Chung KJ, Bennet JE. Medical mycology. Philadelphia: Lea & Febiger Press; 1992. p. 397–446.
- Kwon-Chung KJ, Polacheck I, Bennet JE. Improved diagnostic medium for separation of *Cryptococcus neoformans* var. *neoformans* (serotype A and D) and *Cryptococcus neoformans* var. *gattii* (serotype B and C). *J Clin Microbiol* 1982;15:535–7.
- Vassart G, Georges M, Monsieur R, Brocas H, Lequarre AN, Christophe D. A sequence in M13 phage detects hypervariable minisatellites in human and animal DNA. *Science* 1986;246:683–4.
- Boekhout T, Theelen B, Diaz M, Fell JW, Hop WCJ, Abeln ECA, et al. Hybrid genotypes in the pathogenic yeast *Cryptococcus neoformans*. *Microbiology* 2001; 147:891–907.
- Cogliati M, Allaria M, Liberi G, Tortorano AM, Viviani MA. Sequence analysis and ploidy determination of *Cryptococcus neoformans*. *J Mycol Méd* 2000;10:171–6.
- Franzot SP, Hamdan JS, Currie BP, Casadevall A. Molecular epidemiology of *Cryptococcus neoformans* in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure. *J Clin Microbiol* 1997;35:2243–51.
- Drommer F, Mathoulin S, Dupont B, Laporte A. Epidemiology of cryptococcosis in France: a 9 year survey (1985–1993). *Clin Infect Dis* 1996;23:82–90.
- Viviani MA, Wen H, Roverselli A, Calderelli-Stefano R, Cogliati M, Ferrante P, et al. Identification by polymerase chain reaction fingerprinting of *Cryptococcus neoformans* serotype AD. *Journal of Medical and Veterinary Mycology* 1997;35:355–60.
- Tortorano AM, Viviani MA, Rigoni AL, Cogliati M, Roverselli A, Pagano A. Prevalence of serotype D in *Cryptococcus neoformans* isolates from HIV positive and HIV negative patients in Italy. *Mycoses* 1997;40:297–302.
- Johnston RF. Birds of North America. no 13. Philadelphia: The American Ornithologists Union and the Academy of natural Sciences of Philadelphia; 1992.
- Chen S, Sorrell T, Nimmo G, Speed B, Currie BJ, Marriott D, et al. Epidemiology and host- and variety-dependent characterisation of infection due to *Cryptococcus neoformans* in Australia and New Zealand. *Clin Infect Dis* 2000;31:499–508.
- Hajjeh RA, Conn LA, Stephens DS, Baughman W, Hamill R, Graviss E, et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. *J Infect Dis* 1999;179:449–54.

Address for correspondence: Wieland Meyer, Molecular Mycology Laboratory, CIDM, ICPMR, Level 3, Room 3114A, Westmead Hospital, Darcy Road, Westmead, NSW 2145, Australia; fax : 98915317, e-mail: w.meyer@usyd.edu.au

Appendix Table 1. *Cryptococcus neoformans* clinical, human, and veterinary isolates studied by country, institution characteristics, variety (serotype), and molecular type as identified by PCR fingerprinting with the primer M13 and *URA5* RFLP analysis^a

| LA code | Original code | Year | Original city | Sample | Gender | Age | Risk factor | Variety (serotype) | Molecular type |
|--|---------------|------|-----------------------|-------------|--------|-----|----------------|--------------------|----------------|
| Argentina | | | | | | | | | |
| Hospital Muñiz, Buenos Aires—Human Isolates | | | | | | | | | |
| LA 286# | 135773 | 1999 | Tucumán | CSF | F | 25 | HIV+ | <i>grubii</i> | VNI |
| LA 28# | 135868 | 1999 | Buenos Aires | CSF | F | 24 | HIV+ | <i>grubii</i> | VNI |
| LA 288# | 136725 | 1999 | Buenos Aires | CSF | M | 31 | HIV+ | <i>grubii</i> | VNI |
| LA 289# | 137235 | 1999 | Buenos Aires | Blood | F | 36 | HIV+ | <i>grubii</i> | VNI |
| LA 290# | 136353 | 1999 | | CSF | M | 50 | PCM | <i>gattii</i> | VGIII |
| LA 291# | 137965 | 1999 | Córdoba | Urine | M | 64 | Mielodysplasia | <i>grubii</i> | VNI |
| LA 292# | 144408 | 2000 | Buenos Aires | Blood | M | 28 | HIV+ | <i>grubii</i> | VNI |
| LA 293# | 146323 | 2000 | Buenos Aires | Blood | M | 28 | HIV+ | <i>grubii</i> | VNI |
| LA 294# | 146783 | 2000 | Buenos Aires | CSF | M | 28 | HIV+ | <i>grubii</i> | VNI |
| LA 295 | 143839 | 2000 | Chaco | CSF | M | 40 | none | <i>gattii</i> | VGII |
| LA 296# | 139856 | 1999 | Buenos Aires | Node | M | 35 | HIV+ | <i>grubii</i> | VNI |
| LA 297# | 142181 | 1999 | Buenos Aires | Blood | M | 31 | HIV+ | <i>grubii</i> | VNI |
| LA 298# | 136105 | 1999 | Peru-Buenos Aires | Blood | M | 40 | HIV+ | <i>grubii</i> | VNII |
| LA 299# | 138493 | 1999 | Buenos Aires | Urine | M | 30 | HIV+ | <i>grubii</i> | VNI |
| LA 300# | 138925 | 1999 | Buenos Aires | CSF | M | 31 | HIV+ | <i>grubii</i> | VNI |
| LA 301# | 137154 | 1999 | Buenos Aires | Bone marrow | M | 37 | HIV+ | <i>grubii</i> | VNI |
| LA 302# | 137141 | 1999 | Buenos Aires | Blood | M | 37 | HIV+ | <i>grubii</i> | VNI |
| LA 303# | 137182 | 1999 | Buenos Aires | Blood | M | 25 | HIV+ | <i>grubii</i> | VNI |
| LA 304# | 137921 | 1999 | Buenos Aires | CSF | M | 25 | HIV+ | <i>grubii</i> | VNI |
| LA 305# | 145554 | 1999 | Buenos Aires | Blood | M | 32 | HIV+ | <i>grubii</i> | VNI |
| LA 306# | 145535 | 1999 | Uruguay- Buenos Aires | CSF | M | 35 | HIV+ | <i>grubii</i> | VNI |
| LA 307# | 145469 | 1999 | Buenos Aires | Skin | M | 49 | transplant | <i>grubii</i> | VNI |
| LA 308# | 145516 | 1999 | Buenos Aires | Blood | M | 30 | HIV+ | <i>grubii</i> | VNI |
| LA 309# | 137278 | 1999 | Adroque | CSF | M | 20 | HIV+ | <i>grubii</i> | VNI |
| LA 310# | 140086 | 1999 | Buenos Aires | CSF | F | 29 | HIV+ | <i>grubii</i> | VNI |
| LA 311# | 135610 | 1999 | Buenos Aires | CSF | M | 33 | HIV+ | <i>Hybrid</i> | VNIII* |
| LA 312# | 138860 | 1999 | Buenos Aires | CSF | F | 31 | HIV+ | <i>grubii</i> | VNI |
| LA 313# | 138205 | 1999 | Buenos Aires | CSF | M | 37 | HIV+ | <i>grubii</i> | VNI |
| LA 314# | 138984 | 1999 | Pergamino | CSF | M | 23 | HIV+ | <i>grubii</i> | VNI |
| LA 315# | 140102 | 1999 | Buenos Aires | CSF | M | 26 | HIV+ | <i>grubii</i> | VNI |
| LA 316# | 137939 | 1999 | Buenos Aires | CSF | F | 34 | HIV+ | <i>grubii</i> | VNI |
| LA 318# | 138027 | 1999 | Buenos Aires | BAL | M | 23 | none | <i>grubii</i> | VNI |
| LA 319# | 144687 | 2000 | Buenos Aires | CSF | F | 51 | HIV+ | <i>grubii</i> | VNI |
| LA 320# | 144603 | 2000 | Buenos Aires | Skin | F | 50 | HIV+ | <i>grubii</i> | VNI |
| LA 321# | 137332 | 1999 | Buenos Aires | CSF | M | 55 | HIV+ | <i>Hybrid</i> | VNIII* |
| LA 322# | 135988 | 1999 | Buenos Aires | Blood | M | 54 | HIV+ | <i>grubii</i> | VNI |
| LA 323# | 135887 | 1999 | Buenos Aires | Blood | F | 46 | HIV+ | <i>grubii</i> | VNI |
| LA 324# | 136639 | 1999 | Buenos Aires | CSF | M | 29 | HIV+ | <i>grubii</i> | VNII |
| Departamento Micología, INEI, ANLIS “Dr C.G. Malbran,” Buenos Aires—Human Isolates | | | | | | | | | |
| LA 423# | 00-381 | 2000 | Buenos Aires | BAL | M | 32 | ISP | <i>grubii</i> | VNI |

CDC - Molecular Typing of IberoAmerican *Cryptococcus neoformans* Isolates

| | | | | | | | | | |
|---------|--------|------|--------------|-----|---|----|------|---------------|------|
| LA 424# | 00-345 | 2000 | Jujuy | CSF | | | HIV+ | <i>grubii</i> | VNI |
| LA 425# | 00-343 | 2000 | Buenos Aires | CSF | M | 58 | ND | <i>grubii</i> | VNII |
| LA 426# | 00-284 | 2000 | Misiones | CSF | M | 32 | HIV+ | <i>grubii</i> | VNI |
| LA 427# | 00-236 | 2000 | Mendoza | CSF | | | HIV+ | <i>grubii</i> | VNI |
| LA 428# | 00-364 | 2000 | Buenos Aires | CSF | M | 20 | HIV+ | <i>grubii</i> | VNII |
| LA 429# | 962279 | 1996 | Buenos Aires | CSF | | | HIV+ | <i>grubii</i> | VNI |
| LA 430 | 962278 | 1996 | Buenos Aires | CSF | | | HIV+ | <i>grubii</i> | VNI |
| LA 431# | 961935 | 1996 | Buenos Aires | CSF | | | HIV+ | <i>grubii</i> | VNI |
| LA 432# | 972724 | 1998 | Buenos Aires | CSF | | | HIV+ | <i>grubii</i> | VNI |
| LA 433# | 972756 | 1997 | Buenos Aires | CSF | M | 35 | HIV+ | <i>grubii</i> | VNI |
| LA 434# | 982808 | 1998 | Buenos Aires | CSF | M | 30 | HIV+ | <i>grubii</i> | VNI |
| LA 435# | 983036 | 1998 | Buenos Aires | CSF | M | | HIV+ | <i>grubii</i> | VNI |
| LA 436# | 983039 | 1998 | Buenos Aires | CSF | M | | HIV+ | <i>grubii</i> | VNII |
| LA 437# | 993126 | 1999 | Buenos Aires | CSF | M | 31 | HIV+ | <i>grubii</i> | VNI |

Brazil

Fundação Oswaldo Cruz, Rio de Janeiro—Human Isolates

| | | | | | | | | | |
|--------|-----|------|-------------|-----|---|--|------|---------------|------|
| LA 55# | 417 | 1995 | Piauí State | CSF | M | | | <i>gattii</i> | VGII |
| LA 57 | 506 | 1995 | Piauí State | CSF | M | | | <i>gattii</i> | VGII |
| LA 58# | 512 | 1995 | Piauí State | CSF | F | | | <i>grubii</i> | VNI |
| LA 59# | 513 | 1995 | Piauí State | CSF | M | | | <i>grubii</i> | VNI |
| LA 61# | 557 | 1997 | Piauí State | CSF | F | | HIV+ | <i>gattii</i> | VGII |
| LA 63# | 567 | 1997 | Piauí State | CSF | M | | | <i>grubii</i> | VNI |

Universidade Estadual Paulista, Araraquara—Human Isolates

| | | | | | | | | | |
|---------|---------|------|-----------------------|-----|---|----|------|-------------------|-----|
| LA 346# | 481(5) | 1995 | São José do Rio Preto | CSF | F | 24 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 347# | 482(5) | 1995 | São José do Rio Preto | CSF | F | 24 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 348 | 540(9) | 1995 | São José do Rio Preto | CSF | M | 26 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 349# | 541(9) | 1995 | São José do Rio Preto | CSF | M | 26 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 350# | 14(9) | 1996 | São José do Rio Preto | CSF | M | 26 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 351 | 13(11) | 1996 | São José do Rio Preto | CSF | M | 26 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 352# | 49(11) | 1996 | São José do Rio Preto | CSF | M | 26 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 353# | 98(17) | 1996 | São José do Rio Preto | CSF | M | 40 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 354# | 14(17) | 1996 | São José do Rio Preto | CSF | M | 40 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 355# | 221(23) | 1996 | São José do Rio Preto | CSF | M | 42 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 356# | 18(23) | 1997 | São José do Rio Preto | CSF | M | 42 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 357# | 222(24) | 1996 | São José do Rio Preto | CSF | M | 30 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 358 | 65(24) | 1997 | São José do Rio Preto | CSF | M | 22 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 359# | 62(27) | 1997 | São José do Rio Preto | CSF | M | 29 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 360# | 66(27) | 1997 | São José do Rio Preto | CSF | M | 29 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 361# | 67(27) | 1997 | São José do Rio Preto | CSF | M | 30 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 363# | 1342 | 1993 | Araraquara | CSF | M | 27 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 364# | 1755 | 1997 | Araraquara | CSF | F | 20 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 365# | 1920 | 1998 | Araraquara | CSF | M | 64 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 366# | 2177 | 2000 | Araraquara | CSF | M | 50 | HIV+ | <i>grubii</i> (A) | VNI |

Universidade Estadual Paulista, Araraquara - Veterinary Isolates

| | | | | | | | | | |
|----------|-------|------|-------------|--------------|--|--|--|-------------------|------|
| LA 362 # | Bird1 | 2000 | Jaboticabal | Parrot liver | | | | <i>gattii</i> (B) | VGII |
|----------|-------|------|-------------|--------------|--|--|--|-------------------|------|

Instituto Adolfo Lutz, São Paulo—Human Isolates

| | | | | | | | | | |
|---------|----------|------|-----------|-----|---|----|------|---------------|-----|
| LA 32# | LCS-534 | | São Paulo | CSF | M | 30 | HIV+ | <i>grubii</i> | VNI |
| LA 328# | GFR-1505 | 1997 | São Paulo | CSF | F | 30 | HIV+ | <i>grubii</i> | VNI |

CDC - Molecular Typing of IberoAmerican *Cryptococcus neoformans* Isolates

| | | | | | | | | | |
|---------|-----------|------|-----------|-----|---|----|------|---------------|------|
| LA 329# | AFG-34 | 2000 | São Paulo | CSF | M | 29 | HIV+ | <i>grubii</i> | VNI |
| LA 330# | AFG-14 | 2000 | São Paulo | CSF | M | 30 | HIV+ | <i>grubii</i> | VNI |
| LA 331# | CMS-1226 | 1996 | São Paulo | CSF | M | 28 | HIV+ | <i>grubii</i> | VNI |
| LA 332# | AFG-25/00 | 2000 | São Paulo | CSF | M | 35 | HIV+ | <i>grubii</i> | VNI |
| LA 333# | PRL-1133 | 1996 | São Paulo | CSF | M | 40 | HIV+ | <i>grubii</i> | VNI |
| LA 334# | JCJ-1157 | 1996 | São Paulo | CSF | M | 32 | HIV+ | <i>grubii</i> | VNI |
| LA 335# | MAAC-1866 | 1996 | São Paulo | CSF | M | 36 | HIV+ | <i>grubii</i> | VNI |
| LA 336# | VPD-25 | 1996 | São Paulo | CSF | F | 28 | HIV+ | <i>grubii</i> | VNI |
| LA 337# | AFG-09/00 | 1996 | São Paulo | CSF | M | 30 | HIV+ | <i>gattii</i> | VGII |
| LA 338# | AFG-15/00 | 2000 | São Paulo | CSF | M | 30 | HIV+ | <i>gattii</i> | VGII |
| LA 339# | LCS-394 | 1996 | São Paulo | CSF | M | 31 | HIV+ | <i>grubii</i> | VNI |
| LA 340# | IFOC-1446 | 1996 | São Paulo | CSF | M | 36 | HIV+ | <i>grubii</i> | VNI |
| LA 341# | MO-438 | 1996 | São Paulo | CSF | M | 34 | HIV+ | <i>grubii</i> | VNI |
| LA 342# | KSO-948 | 1996 | São Paulo | CSF | M | 23 | HIV+ | <i>grubii</i> | VNI |
| LA 343# | CSC-1016 | 1996 | São Paulo | CSF | M | 34 | HIV+ | <i>grubii</i> | VNII |
| LA 344# | MDS-949 | 1996 | São Paulo | CSF | M | 32 | HIV+ | <i>grubii</i> | VNI |
| LA 345# | MEM-1064 | 1996 | São Paulo | CSF | M | 33 | HIV+ | <i>grubii</i> | VNI |

Centro de Biotecnologia, Porto Alegre—Human Isolates

| | | | | | | | | | |
|--------|------|------|--------------|-----|---|----|------|-------------------|------|
| LA 755 | HC2 | 2000 | Porto Alegre | CSF | M | 38 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 756 | HC3 | 2000 | Porto Alegre | CSF | M | 38 | HIV+ | <i>grubii</i> (A) | VNII |
| LA 757 | HC4 | 2000 | Porto Alegre | CSF | F | 36 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 758 | HC6 | 2000 | Porto Alegre | CSF | M | 46 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 759 | HC8 | 2000 | Porto Alegre | CSF | M | 40 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 760 | HC9 | 2000 | Porto Alegre | CSF | M | 33 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 761 | HC10 | 2000 | Porto Alegre | CSF | M | 29 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 762 | HC11 | 2000 | Porto Alegre | CSF | F | 50 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 763 | HC13 | 2000 | Porto Alegre | CSF | M | 42 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 764 | HC14 | 2000 | Porto Alegre | CSF | M | 29 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 765 | HC15 | 2000 | Porto Alegre | CSF | F | 55 | HIV+ | <i>grubii</i> (A) | VNI |

Chile

Universidad de Chile, Santiago de Chile—Human Isolates

| | | | | | | | | | |
|---------|-------|------|--------------|---------------|---|----|------|-------------------|--------|
| LA 256# | CR-01 | 1990 | Santiago | Blood | M | | HIV+ | <i>neoformans</i> | VNIV |
| LA 258 | CR-03 | 1991 | Santiago | CSF | M | | HIV+ | Hybrid | VNIII* |
| LA 259# | CR-06 | 1991 | Santiago | Blood | M | | HIV+ | <i>neoformans</i> | VNIV |
| LA 260 | CR-10 | 1995 | Santiago | Blood | M | | HIV+ | Hybrid | VNIII |
| LA 262# | CR-12 | 1997 | Santiago | Blood | M | 33 | HIV+ | <i>neoformans</i> | VNIV |
| LA 263 | CR-16 | 1998 | Santiago | CSF | M | | HIV+ | Hybrid | VNIII |
| LA 264# | CR-21 | 1997 | Santiago | Pleural fluid | M | | ND | <i>grubii</i> | VNI |
| LA 267# | CR-26 | 2000 | Santiago | Abscess | M | | HIV+ | <i>grubii</i> | VNII |
| LA 268# | CR-27 | 2000 | Santiago | Blood | M | | HIV+ | <i>neoformans</i> | VNIV |
| LA 269# | CR-29 | 2000 | Santiago | BAL | M | 57 | HIV+ | <i>grubii</i> | VNI |
| LA 270# | CR-30 | 2000 | Santiago | Blood | M | | HIV+ | <i>grubii</i> | VNI |
| LA 271# | CR-31 | 2000 | Santiago | Blood | M | | HIV+ | <i>grubii</i> | VNI |
| LA 272# | CR-34 | 2000 | Santiago | CSF | M | 29 | HIV+ | <i>neoformans</i> | VNIV |
| LA 273# | CR-35 | 2000 | Viña del Mar | CSF | M | 35 | HIV+ | <i>grubii</i> | VNII |
| LA 274# | CR-36 | 2000 | Santiago | CSF | M | | ND | <i>grubii</i> | VNII |

Colombia

Instituto Nacional de Salud, Bogotá—Human Isolates

CDC - Molecular Typing of IberoAmerican *Cryptococcus neoformans* Isolates

| | | | | | | | | | |
|---|----------------|------|----------------|-------|---|----|-------|-----------------------|-------|
| LA 214# | H0058-I-138 | 1991 | Tolima | CSF | F | 4 | None | <i>grubii</i> (A) | VNI |
| LA 461# | H0058-I-34 | 1986 | Casanare | CSF | F | 16 | None | <i>gattii</i> (B) | VGII |
| LA 469# | H0058-I-43 | 1987 | Cundinamarca | CSF | M | 67 | ND | <i>grubii</i> (A) | VNII |
| LA 472# | H0058-I-50 | 1988 | Antioquia | CSF | F | | HIV+ | <i>grubii</i> (A) | VNI |
| LA 473# | H0058-I-57 | 1988 | Bogotá | CSF | M | 58 | None | <i>grubii</i> (A) | VNI |
| LA 478# | H0058-I-62 | 1988 | Bogotá | CSF | F | 16 | Lupus | <i>grubii</i> (A) | VNI |
| LA 479# | H0058-I-64 | 1988 | Huila | CSF | M | 33 | None | <i>grubii</i> (A) | VNI |
| LA 481# | H0058-I-67 | 1989 | N. Santander | CSF | M | 46 | None | <i>grubii</i> (A) | VNI |
| LA 487# | H0058-I-78 | 1989 | Arauca | CSF | M | 43 | None | <i>gattii</i> (C) | VGIII |
| LA 495 | H0058-I-96 | 1990 | Cundinamarca | CSF | M | | None | <i>grubii</i> (A) | VNI |
| LA 498 | H0058-I-103 | 1990 | Antioquia | CSF | M | 65 | None | <i>grubii</i> (A) | VNI |
| LA 499# | H0058-I-106 | 1990 | N. Santander | CSF | M | 44 | None | <i>gattii</i> (B) | VGII |
| LA 506# | H0058-I-160 | 1992 | Tolima | CSF | M | 28 | None | <i>grubii</i> (A) | VNI |
| LA 511 | H0058-I-190 | 1992 | Bogotá | CSF | M | 34 | HIV+ | <i>grubii</i> (A) | VNII |
| LA 516# | H0058-I-212 | 1993 | N. Santander | CSF | M | 54 | None | <i>gattii</i> (B) | VGII |
| LA 518# | H0058-I-229 | 1993 | Bogotá | CSF | M | 33 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 521# | H0058-I-232 | 1993 | Bogotá | CSF | M | 30 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 523# | H0058-I-238 | 1994 | Bogotá | CSF | M | 42 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 525 | H0058-I-246 | 1994 | Bogotá | CSF | M | 65 | None | <i>grubii</i> (A) | VNI |
| LA 550# | H0058-I-471 | 1996 | Nariño | CSF | M | 35 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 552# | H0058-I-473 | 1997 | Bogotá | CSF | M | 40 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 564 | H0058-I-628 | 1997 | Bogotá | CSF | M | 29 | None | <i>gattii</i> (B) | VGI |
| LA 567# | H0058-I-638 | 1997 | Caquetá | CSF | F | 34 | None | <i>gattii</i> (B) | VGII |
| LA 568 | H0058-I-642 | 1997 | Boyacá | CSF | M | 36 | None | <i>gattii</i> (B) | VGIV |
| LA 572# | H0058-I-653 | 1998 | Cundinamarca | CSF | M | 57 | HIV+ | <i>grubii</i> (A) | VNII |
| LA 584# | H0058-I-675 | 1998 | Bolivar | CSF | M | 23 | None | <i>gattii</i> (B) | VGII |
| LA 590# | H0058-I-762 | 1998 | Santander | CSF | M | 48 | None | <i>gattii</i> (B) | VGII |
| LA 593# | H0058-I-789 | 1998 | Bogotá | CSF | M | 23 | HIV+ | <i>neoformans</i> (D) | VNIV |
| LA 595# | H0058-I-828 | 1998 | Bogotá | CSF | M | 52 | HIV+ | <i>grubii</i> (A) | VNII |
| LA 599# | H0058-I-881 | 1999 | N. Santander | CSF | M | 33 | None | <i>gattii</i> (B) | VGII |
| LA 602# | H0058-I-889 | 1999 | Bogotá | CSF | M | 42 | HIV+ | <i>grubii</i> (A) | VNII |
| LA 603# | H0058-I-902 | 1999 | Arauca | CSF | M | 50 | None | <i>grubii</i> (A) | VNII |
| LA 615# | H0058-I-1068 | 2000 | Antioquia | CSF | M | 33 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 620 | H0058-I-1097 | 2000 | Antioquia | BAL | M | 19 | HIV+ | <i>grubii</i> (A) | VNII |
| LA 622# | H0058-I-1134 | 2000 | Risaralda | CSF | F | 41 | ND | <i>gattii</i> (B) | VGIII |
| LA 628# | H0058-I-1198 | 2001 | Bogotá | CSF | M | 23 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 629# | H0058-I-1199 | 2001 | Bogotá | CSF | M | 43 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 752 | H0058-I-1276 | 2001 | N. Santander | CSF | M | 29 | None | <i>gattii</i> (C) | VGIII |
| LA 753# | H0058-I-1278 | 2001 | N. Santander | CSF | M | 39 | None | <i>gattii</i> (B) | VGII |
| Guatemala | | | | | | | | | |
| Hospital San Juan de Dios and Universidad de San Carlos, Guatemala—Human Isolates | | | | | | | | | |
| LA 737# | 134 | 2000 | Guatemala City | CSF | F | | HIV+ | <i>grubii</i> (A) | VNI |
| LA 738# | 188 | 2000 | Guatemala City | CSF | M | 57 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 739# | 415 | 2001 | Guatemala City | Blood | M | | ND | <i>grubii</i> (A) | VNI |
| LA 740# | 600 | 2000 | Guatemala City | CSF | M | 53 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 741 | C.9 | | | | | | | <i>grubii</i> (A) | VNI |
| LA 742# | C.9.4.67.BM(1) | | | | | | | <i>grubii</i> (A) | VNI |
| LA 743 | C.9.7.17.G2(1) | | | | | | | <i>grubii</i> (A) | VNI |

CDC - Molecular Typing of IberoAmerican Cryptococcus neoformans Isolates

| | | | | | | | | | | |
|---------|-----------------|------|--|-----|---|----|--|-------------------|-------------------|-------|
| LA 744 | C.9.98RM3-6 | | | | | | | <i>grubii</i> (A) | VNI | |
| LA 745 | C.9.10.11.BG(2) | | | | | | | <i>grubii</i> (A) | VNI | |
| LA 746 | C.9.11.60AG1(1) | | | | | | | <i>grubii</i> (A) | VNI | |
| LA 747 | 2591 | 2000 | | CSF | M | | | ND | <i>grubii</i> (A) | VNI |
| LA 748 | 3308 | 2000 | | CSF | M | | | ND | <i>grubii</i> (A) | VNI |
| LA 749# | 3417 | 2000 | | | | | | ND | <i>grubii</i> (A) | VNI |
| LA 750# | 2361 | 2000 | | | F | 14 | | ND | <i>gattii</i> | VGIII |
| LA 751# | 193 | 2000 | | CSF | M | 57 | | HIV+ | <i>grubii</i> (A) | VNI |

Mexico

Universidad Nacional Autonoma de Mexico, Mexico City—Human Isolates

| | | | | | | | | | | |
|--------|-----|------|--------------|-------|---|----|--|-------|-------------------|--------|
| LA 1# | 116 | 1994 | Mexico City | CSF | M | 19 | | None | <i>gattii</i> (B) | VGI |
| LA 2# | 117 | 1994 | Mexico City | CSF | M | 35 | | Tumor | <i>gattii</i> (B) | VGI |
| LA 3 | 122 | 1986 | Mexico City | CSF | F | 10 | | None | <i>gattii</i> (B) | VGIII |
| LA 4# | 174 | 1996 | Texcoco, Edo | CSF | F | 15 | | IMS | <i>grubii</i> | VNI |
| LA 5 | 190 | 1995 | Mexico City | CSF | F | 45 | | None | <i>gattii</i> | VGIII |
| LA 6# | 194 | 1995 | Mexico City | CSF | M | 27 | | HIV+ | <i>grubii</i> | VNI |
| LA 7# | 196 | 1995 | Mexico City | CSF | M | 27 | | HIV+ | <i>grubii</i> | VNI |
| LA 8# | 202 | 1996 | Mexico City | CSF | M | 38 | | HIV+ | <i>grubii</i> | VNI |
| LA 9# | 204 | 1996 | Mexico City | CSF | M | 39 | | None | <i>gattii</i> | VGI |
| LA 10 | 205 | 1996 | Mexico City | CSF | M | 67 | | None | <i>grubii</i> | VNI |
| LA 11# | 207 | 1996 | Mexico City | CSF | M | 33 | | HIV+ | <i>grubii</i> | VNI |
| LA 12# | 209 | 1996 | Mexico City | CSF | M | 35 | | IMS | <i>grubii</i> | VNI |
| LA 13# | 216 | 1996 | Mexico City | CSF | M | 46 | | None | <i>grubii</i> | VNI |
| LA 14# | 218 | 1997 | Mexico City | CSF | M | 47 | | HIV+ | Hybrid | VNIII* |
| LA 15# | 220 | 1997 | Mexico City | CSF | M | 34 | | HIV+ | <i>grubii</i> | VNI |
| LA 16# | 221 | 1996 | Mexico City | CSF | F | 17 | | None | <i>gattii</i> | VGIII |
| LA 17# | 223 | 1996 | Mexico City | CSF | M | 27 | | HIV+ | <i>grubii</i> | VNI |
| LA 18# | 224 | 1996 | Mexico City | CSF | M | 31 | | HIV+ | <i>gattii</i> | VGIII |
| LA 19 | 225 | 1997 | Mexico City | Blood | M | 29 | | HIV+ | <i>grubii</i> | VNI |
| LA 20 | 227 | 1997 | Mexico City | CSF | M | 36 | | HIV+ | <i>gattii</i> | VGIII |

Instituto Nacional de Diagnostica y Referencia Epidemiologicos, Mexico City—Human Isolates

| | | | | | | | | | | |
|---------|------|------|------------------|------------|---|----|--|------|---------------|-------|
| LA 390# | 5604 | 1961 | Distrito Federal | CSF | M | 38 | | ND | <i>gattii</i> | VGIV |
| LA 391# | 5605 | 1962 | Distrito Federal | CSF | M | 47 | | ND | <i>gattii</i> | VGIV |
| LA 392# | 5606 | 1965 | Distrito Federal | CSF | M | 40 | | ND | <i>gattii</i> | VGIV |
| LA 393 | 5607 | 1965 | Distrito Federal | CSF | M | 52 | | ND | <i>grubii</i> | VNI |
| LA 394# | 5608 | 1967 | Distrito Federal | CSF | M | 41 | | ND | <i>grubii</i> | VNI |
| LA 396# | 5611 | 1970 | Distrito Federal | CSF | M | 33 | | ND | <i>grubii</i> | VNI |
| LA 397# | 5613 | 1973 | Distrito Federal | CSF | M | 47 | | ND | <i>grubii</i> | VNI |
| LA 398# | 5615 | 1978 | Distrito Federal | Skin | M | 59 | | ND | <i>grubii</i> | VNI |
| LA 399# | 5616 | 1980 | Distrito Federal | Lungs, CSF | M | 59 | | ND | <i>gattii</i> | VGIII |
| LA 400# | 5617 | 1980 | Distrito Federal | CSF | F | 32 | | ND | <i>gattii</i> | VGIII |
| LA 402# | 5619 | 1982 | Distrito Federal | CSF | M | 35 | | ND | <i>gattii</i> | VGIII |
| LA 403 | 5620 | 1986 | Distrito Federal | CSF | F | 11 | | ND | <i>gattii</i> | VGIII |
| LA 404# | 5621 | 1987 | Michoacan | CSF | M | 47 | | ND | <i>grubii</i> | VNII |
| LA 405# | 5622 | 1988 | Distrito Federal | CSF | M | 43 | | ND | <i>grubii</i> | VNI |
| LA 406# | 5623 | 1990 | Distrito Federal | CSF | M | 34 | | HIV+ | <i>grubii</i> | VNI |
| LA 407 | 5624 | 1990 | Distrito Federal | CSF | M | 46 | | ND | <i>gattii</i> | VGIII |
| LA 408 | 5625 | 1991 | Distrito Federal | Blood | M | 49 | | ND | <i>grubii</i> | VNI |

CDC - Molecular Typing of IberoAmerican *Cryptococcus neoformans* Isolates

| | | | | | | | | | |
|---------|------|------|------------------|-----|---|----|------|---------------|-------|
| LA 409# | 5626 | 1992 | Distrito Federal | CSF | M | 53 | HIV+ | <i>grubii</i> | VNI |
| LA 410# | 5627 | 1992 | Distrito Federal | CSF | M | 37 | HIV+ | <i>grubii</i> | VNI |
| LA 411 | 5628 | 1991 | Distrito Federal | CSF | M | 29 | ND | <i>gattii</i> | VGIII |
| LA 412# | 5629 | 1997 | Distrito Federal | CSF | M | 58 | ND | <i>gattii</i> | VGIII |
| LA 413# | 5630 | 1998 | Distrito Federal | CSF | M | 30 | HIV+ | <i>grubii</i> | VNI |
| LA 414# | 5631 | 1999 | Distrito Federal | CSF | M | 28 | ND | <i>gattii</i> | VGIII |
| LA 415# | 5632 | 1999 | Distrito Federal | CSF | M | 36 | ND | <i>grubii</i> | VNI |
| LA 416# | 5633 | 1999 | Distrito Federal | CSF | M | 42 | HIV+ | <i>grubii</i> | VNI |
| LA 417# | 5634 | 1999 | Distrito Federal | CSF | M | 33 | HIV+ | <i>grubii</i> | VNI |

Peru

Instituto de Medicina Tropical Alexander von Humboldt, Lima—Human Isolates

| | | | | | | | | | |
|---------|-----------|------|------|--------------|---|----|------|---------------|-----|
| LA 153# | 39401/U | 1998 | Lima | Urine | M | 27 | HIV+ | <i>grubii</i> | VNI |
| LA 154# | 39401/S | 1998 | Lima | Sputum | M | 27 | HIV+ | <i>grubii</i> | VNI |
| LA 155# | 39401/B | 1998 | Lima | Blood | M | 27 | HIV+ | <i>grubii</i> | VNI |
| LA 156 | 39407/CSF | 1998 | Lima | CSF | M | 30 | HIV+ | <i>grubii</i> | VNI |
| LA 157# | 39407/B | 1998 | Lima | Blood | M | 30 | HIV+ | <i>grubii</i> | VNI |
| LA 158# | 39408/CSF | 1998 | Lima | CSF | M | 22 | HIV+ | <i>grubii</i> | VNI |
| LA 159# | 39408/U | 1998 | Lima | Urine | M | 22 | HIV+ | <i>grubii</i> | VNI |
| LA 160# | 39408/B | 1998 | Lima | Blood | M | 22 | HIV+ | <i>grubii</i> | VNI |
| LA 162# | 39410/U | 1998 | Lima | Urine | F | 36 | HIV+ | <i>grubii</i> | VNI |
| LA 163# | 39410/B | 1998 | Lima | Blood | F | 36 | HIV+ | <i>grubii</i> | VNI |
| LA 164 | 39410/BM | 1998 | Lima | Blood marrow | F | 36 | HIV+ | <i>grubii</i> | VNI |
| LA 169 | 8640 | 1988 | Lima | Abscesses | M | 66 | None | <i>grubii</i> | VNI |
| LA 170# | 15335 | 1993 | Lima | CSF | M | 36 | None | <i>gattii</i> | VGI |

Spain

GREMEC, IMM/UAB, Barcelona—Human Isolates

| | | | | | | | | | |
|---------|------|------|-----------|-------|---|--|------|-------------------|---------|
| LA 180# | 154c | 1995 | Barcelona | Blood | F | | HIV+ | Hybrid (A, AD) | VNIII |
| LA 181# | 155c | 1995 | Barcelona | CSF | M | | HIV+ | Hybrid (A, AD) | VNIII |
| LA 182# | 156c | 1995 | Barcelona | Blood | M | | HIV+ | <i>grubii</i> (A) | VNI |
| LA 183# | 1c | 1994 | Valencia | CSF | M | | HIV+ | Hybrid (AD, D) | VNIII* |
| LA 184# | 2c | 1994 | Valencia | CSF | F | | HIV+ | Hybrid (AD, D) | VNIII* |
| LA 185# | 3c | 1994 | Valencia | CSF | M | | HIV+ | Hybrid (AD, D) | VNIII** |
| LA 186# | 73c | 1994 | Sevilla | CSF | M | | HIV+ | Hybrid (AD) | VNIII |
| LA 187# | 74c | 1995 | Sevilla | CSF | M | | HIV+ | <i>grubii</i> (A) | VNI |
| LA 188# | 75c | 1995 | Sevilla | CSF | M | | HIV+ | Hybrid (AD) | VNIII* |

GREMEC, IMM/UAB, Barcelona—Veterinary Isolates:

| | | | | | | | | | |
|---------|------|------|---------|------|--|--|--|-------------------|-----|
| LA 174# | 48 A | 1995 | Cáceres | Goat | | | | <i>gattii</i> (B) | VGI |
| LA 175# | 50 A | 1995 | Cáceres | Goat | | | | <i>gattii</i> (B) | VGI |
| LA 176# | 52 A | 1995 | Cáceres | Goat | | | | <i>gattii</i> (B) | VGI |
| LA 177# | 54 A | 1995 | Cáceres | Goat | | | | <i>gattii</i> (B) | VGI |
| LA 178# | 56 A | 1995 | Cáceres | Goat | | | | <i>gattii</i> (B) | VGI |
| LA 179# | 58 A | 1995 | Cáceres | Goat | | | | <i>gattii</i> (B) | VGI |

Venezuela

Universidad del Zulia, Maracaibo—Human Isolates

| | | | | | | | | | |
|---------|-----------|------|---------|-----|---|----|----------|-------------------|------|
| LA 367# | BVC125-96 | 1996 | Caracas | ND | F | 36 | HIV+ | <i>grubii</i> (A) | VNII |
| LA 368# | BV1742 | 1996 | Caracas | CSF | M | 66 | leukemia | <i>grubii</i> (A) | VNI |
| LA 369# | BV2086 | 1996 | Caracas | CSF | M | 34 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 370# | BV2098 | 1996 | Caracas | CSF | M | 28 | HIV+ | <i>grubii</i> (A) | VNI |

CDC - Molecular Typing of IberoAmerican *Cryptococcus neoformans* Isolates

| | | | | | | | | | |
|---------|----------|------|-----------|-----|---|-------|------------|-------------------|-------|
| LA 371# | BV2189 | 1996 | Caracas | CSF | M | 26 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 372# | BV2198 | 1996 | Caracas | CSF | M | Adult | HIV+ | <i>grubii</i> (A) | VNI |
| LA 373# | BV2199 | 1996 | Caracas | CSF | M | 34 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 374# | BV2244 | 1997 | Caracas | CSF | M | Adult | HIV+ | <i>grubii</i> (A) | VNI |
| LA 375# | BV2293 | 1997 | Caracas | CSF | M | Adult | HIV+ | <i>grubii</i> (A) | VNI |
| LA 376# | BV2379 | 1997 | Caracas | CSF | M | Adult | HIV+ | <i>grubii</i> (A) | VNI |
| LA 377 | BV2450 | 1997 | Maracaibo | CSF | M | Adult | HIV+ | <i>grubii</i> (A) | VNI |
| LA 379 | BV1 | 1995 | Maracaibo | CSF | M | 28 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 380 | BV2 | 1995 | Maracaibo | CSF | M | 19 | HIV+ | <i>grubii</i> (A) | VNI |
| LA 381# | BV5 | 1996 | Maracaibo | CSF | M | 30 | None | <i>gattii</i> (B) | VGII |
| LA 382# | BV19 | 1997 | Maracaibo | CSF | M | 32 | None | <i>gattii</i> (C) | VGIII |
| LA 383# | BV201A | 1997 | Maracaibo | CSF | M | 41 | Transplant | <i>grubii</i> (A) | VNI |
| LA 384 | BV170cli | 1999 | Maracaibo | CSF | M | 73 | None | <i>grubii</i> | VNI |
| LA 385# | BV1118 | 1999 | Maracaibo | CSF | M | 30 | None | <i>grubii</i> | VNI |
| LA 386# | BV1218 | 1999 | Maracaibo | CSF | F | 42 | MS | <i>gattii</i> | VGII |
| LA 387# | BV1297 | 1999 | Maracaibo | CSF | F | 25 | Diabetes | <i>gattii</i> | VGII |

^aPCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; GREMEC, IMM/UAB,; CSF, cerebrospinal fluid; F, female; M, male; BAL, bronchoalveolar lavage; ISP, immunosupressed; MS, multiple sclerosis; ND, no data; VNIII, seven-band *URA5* RFLP pattern; VNIII*, six-band *URA5* RFLP pattern; *, strains included in the GelcomparII analysis.

Appendix Table 2. *Cryptococcus neoformans* environmental isolates studied by country, institution characteristics, variety (serotype) and molecular type as identified by PCR-fingerprinting with the primer M13 and *URA5* RFLP analysis^a

| LA Code | Original code | Year | Original city | Sample | Variety (serotype) | Molecular type |
|---|---------------|------|----------------|----------------------------------|--------------------|----------------|
| Argentina | | | | | | |
| Departamento Micología, INEI, ANLIS "Dr C.G. Malbran," Buenos Aires | | | | | | |
| LA 438# | Cr34Eb | 2000 | Buenos Aires | Trees | <i>grubii</i> | VNI |
| LA 440# | CrA29 | 2000 | Buenos Aires | Trees | <i>grubii</i> | VNI |
| LA 441# | Cr10 | 2000 | Buenos Aires | Trees | <i>gattii</i> | VGI |
| LA 442# | CrA32 | 2000 | Buenos Aires | Trees | <i>grubii</i> | VNI |
| Brazil | | | | | | |
| Fundação Oswaldo Cruz, Rio de Janeiro | | | | | | |
| LA 44# | 414 | 1995 | Piauí State | Pottery tree hollow | <i>gattii</i> (B) | VGII |
| LA 45# | 415 | 1995 | Piauí State | Pink shower tree hollow | <i>gattii</i> (B) | VGII |
| LA 47# | 434 | 1996 | Piauí State | <i>E. camaldulensis</i> debris | <i>gattii</i> (B) | VGII |
| LA 52# | 561 | 1997 | Piauí State | Pink shower tree hollow | <i>grubii</i> | VNI |
| LA 54 | 564 | 1997 | Piauí State | Pink shower tree hollow | <i>grubii</i> | VNI |
| LA 419# | WM1012 | 2000 | Rio de Janeiro | Pink shower tree 4, large hollow | <i>grubii</i> | VNI |
| LA 420# | WM1013 | 2000 | Rio de Janeiro | Pink shower tree 4, large hollow | <i>grubii</i> | VNI |
| LA 421# | WM1014 | 2000 | Rio de Janeiro | Pink shower tree 4, large hollow | <i>grubii</i> | VNI |
| LA 422# | WM1015 | 2000 | Rio de Janeiro | Pink shower tree 4, large hollow | <i>grubii</i> | VNI |
| Chile | | | | | | |
| Universidad de Chile, Santiago de Chile | | | | | | |
| LA 276# | 04-A | 1993 | Santiago | Bird droppings | <i>grubii</i> | VNI |
| LA 277# | 06-A | 1993 | Santiago | Bird droppings | <i>grubii</i> | VNI |
| LA 281 | 21-A | 1993 | Santiago | Bird droppings | <i>grubii</i> | VNI |
| LA 284# | 52-A | 1993 | Santiago | Bird droppings | <i>grubii</i> | VNI |
| Colombia | | | | | | |
| Instituto Nacional de Salud, Bogota | | | | | | |
| LA 235# | H0058-I-737 | 1998 | N. Santander | Almond tree (9) | <i>gattii</i> (C) | VGIII |
| LA 241 | H0058-I-1014 | 1999 | N. Santander | Almond tree (20) | <i>gattii</i> (C) | VGIII |
| LA 631# | H0058-I-556 | 1997 | N. Santander | Almond tree (9) | <i>gattii</i> (C) | VGIII |
| LA 645# | H0058-I-607 | 1997 | N. Santander | Almond tree (9) | <i>grubii</i> | VNI |
| LA 651 | H0058-I-613 | 1997 | N. Santander | Almond tree (9) | <i>gattii</i> (C) | VGIII |
| LA 658# | H0058-I-679 | 1998 | N. Santander | Almond tree (9) | <i>grubii</i> (A) | VNI |
| LA 659 | H0058-I-682 | 1998 | N. Santander | Almond tree (21) | <i>gattii</i> (C) | VGIII |
| LA 667 | H0058-I-755 | 1998 | N. Santander | Almond tree (9) | <i>gattii</i> (C) | VGIII |
| LA 672 | H0058-I-798 | 1998 | N. Santander | Almond tree (9) | <i>gattii</i> (C) | VGIV |
| LA 674 | H0058-I-818 | 1998 | N. Santander | Almond tree (9) | <i>gattii</i> (C) | VGIII |
| LA 676 | H0058-I-820 | 1998 | N. Santander | Almond tree (9) | <i>gattii</i> (C) | VGIII |
| LA 680 | H0058-I-826 | 1998 | N. Santander | Almond tree (9) | <i>gattii</i> (C) | VGIII |
| LA 684# | H0058-I-908 | 1998 | N. Santander | Almond tree (9) | <i>gattii</i> (C) | VGIII |
| LA 688 | H0058-I-548 | 1996 | N. Santander | House patient 3 | <i>grubii</i> (A) | VNI |
| LA 691# | H0058-I-551 | 1996 | N. Santander | Older oiti tree | <i>grubii</i> (A) | VNI |
| LA 706# | H0058-I-587 | 1996 | N. Santander | Oiti tree | <i>grubii</i> (A) | VNI |
| LA 710# | H0058-I-595 | 1996 | N. Santander | Acacia tree (1) | <i>grubii</i> (A) | VNI |

CDC - Molecular Typing of IberoAmerican Cryptococcus neoformans Isolates

| | | | | | | |
|---|-------------|------|------------------|--|-------------------|-------|
| LA 714 | H0058-I-599 | 1997 | N. Santander | Acacia tree (6) | <i>gattii</i> | VGIII |
| LA 720# | H0058-I-735 | 1998 | Bogotá | <i>Eucalyptus</i> tree (13) | <i>grubii</i> (A) | VNI |
| LA 726# | H0058-I-745 | 1997 | N. Santander | Cuji tree | <i>grubii</i> (A) | VNI |
| LA 731 | H0058-I-752 | 1997 | N. Santander | Seed of almond tree | <i>grubii</i> (A) | VNI |
| LA 733# | H0058-I-757 | 1997 | N. Santander | Cuji, tree | <i>gattii</i> | VGIII |
| LA 736 | H0058-I-857 | 1998 | Bogotá | <i>Eucalyptus</i> tree | <i>grubii</i> (A) | VNI |
| Mexico | | | | | | |
| Universidad Nacional Autonoma de Mexico, Mexico City | | | | | | |
| LA 21# | 88 | 1994 | Mexico City | Green parrot droppings | <i>grubii</i> | VNI |
| LA 22# | 89 | 1994 | Mexico City | Budgerigar droppings | <i>grubii</i> | VNI |
| LA 23# | 90 | 1994 | Mexico City | Budgerigar droppings | <i>grubii</i> | VNI |
| LA 24# | 146 | 1995 | Mexico City | Pigeon droppings | <i>grubii</i> | VNI |
| LA 25# | 147 | 1995 | Mexico City | Pigeon droppings | <i>grubii</i> | VNI |
| LA 26# | 148 A | 1995 | Mexico City | Pigeon droppings | <i>grubii</i> | VNI |
| LA 27# | 148 B | 1995 | Mexico City | Pigeon droppings | <i>grubii</i> | VNI |
| LA 28# | 149 | 1995 | Mexico City | Pigeon droppings | <i>grubii</i> | VNI |
| LA 29# | 150 A | 1995 | Mexico City | Pigeon droppings | <i>grubii</i> | VNI |
| LA 30# | 150 B | 1995 | Mexico City | Pigeon droppings | <i>grubii</i> | VNI |
| LA 31# | 151 | 1995 | Mexico City | Pigeon droppings | <i>grubii</i> | VNI |
| LA 32# | 152 | 1995 | Mexico City | Pigeon droppings | <i>grubii</i> | VNI |
| LA 33 | 164 | 1995 | Mexico City | Pigeon droppings | <i>grubii</i> | VNI |
| LA 34# | 165 | 1995 | Mexico City | Pigeon droppings | <i>grubii</i> | VNI |
| LA 35# | 168 | 1995 | Mexico City | Pigeon droppings | <i>grubii</i> | VNI |
| LA 36# | 170 | 1995 | Mexico City | Pigeon droppings | <i>grubii</i> | VNI |
| LA 37# | 230 | 1998 | Edo, Mexico | <i>E. camaldulensis</i> (leaves and flowers) | <i>grubii</i> | VNI |
| LA 38# | 234 | 1998 | Edo, Mexico | <i>E. camaldulensis</i> (leaves and flowers) | <i>grubii</i> | VNI |
| LA 39# | 235 | 1998 | Edo, Mexico | <i>E. camaldulensis</i> (leaves and flowers) | <i>grubii</i> | VNI |
| LA 40# | 237 | 1998 | Edo, Mexico | <i>E. camaldulensis</i> (leaves and flowers) | <i>grubii</i> | VNI |
| LA 41# | 238 | 1998 | Edo, Mexico | <i>E. camaldulensis</i> (leaves and flowers) | <i>grubii</i> | VNI |
| LA 42 | 239 | 1998 | Edo, Mexico | <i>E. camaldulensis</i> (leaves and flowers) | <i>grubii</i> | VNI |
| Instituto Nacional de Diagnostica y Referencia Epidemiologicos, Mexico City | | | | | | |
| LA 418# | 5635 | 2000 | Distrito Federal | Pigeon excreta | <i>grubii</i> | VNI |
| Spain | | | | | | |
| GREMEC, IMM/UAB, Barcelona | | | | | | |
| LA 189 # | 152 A | 1999 | Barcelona | Pigeon droppings | <i>grubii</i> (A) | VNI |
| LA 190 # | 76 A | 1999 | Barcelona | Pigeon droppings | <i>grubii</i> (A) | VNI |
| LA 192 # | 4 A | 1997 | Alacant | Pigeon droppings | Hybrid (A)(AD) | VNIII |
| LA 193 # | 6 A | 1997 | Alacant | Pigeon droppings | <i>grubii</i> (A) | VNI |

^aRFLP, restriction fragment length polymorphism; INEI, Instituto Nacional de Enfermedades Infecciosas; ANLIS, Administracion Nacional de Laboratorios e Institutos de Salud; GREMEC, Grup de Recerca en Micologia Experimental i Clinica; IMM, Institut Municipal d' Investigacio Medica; UAB, Universita Autonoma de Barcelona.

^bVNIII: seven-band *URA5* RFLP pattern; VNIII*, six-band *URA5* RFLP pattern; *, strains included in the GelcomparII analysis